A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer's disease

被引:93
|
作者
Jalili-Baleh, Leili [1 ]
Babaei, Elaheh [2 ]
Abdpour, Shahin [3 ]
Bukhari, Syed Nasir Abbas [4 ]
Foroumadi, Alireza [1 ,5 ]
Ramazani, Ali [3 ]
Sharifzadeh, Mohammad [6 ]
Abdollahi, Mohammad [1 ]
Khoobi, Mehdi [1 ,7 ]
机构
[1] Univ Tehran Med Sci, TIPS, Tehran 1417614411, Iran
[2] Yazd Univ, Dept Chem, Fac Sci, Yazd, Iran
[3] Univ Zanjan, Dept Chem, Zanjan, Iran
[4] Jouf Univ, Dept Pharmaceut Chem, Coll Pharm, Aljouf 2014, Sakaka, Saudi Arabia
[5] Univ Tehran Med Sci, Dept Med Chem, Fac Pharm, Tehran, Iran
[6] Univ Tehran Med Sci, Dept Pharmacol & Toxicol, Toxicol & Poisoning Res Ctr, Fac Pharm, Tehran, Iran
[7] Univ Tehran Med Sci, Dept Pharmaceut Biomat, Fac Pharm, Tehran, Iran
关键词
Chromanone; Multi-target drug ligands (MTDLs); Cholinesterase; Beta-secretase; Monoamine oxidase; Amyloid-beta; MONOAMINE-OXIDASE-B; BETA-SECRETASE BACE-1; ACETYLCHOLINESTERASE INHIBITORS; MULTIFUNCTIONAL AGENTS; FIBRIL FORMATION; CHROMONE DERIVATIVES; MOUSE MODEL; IN-VITRO; ANTICHOLINESTERASE ACTIVITY; PHARMACOLOGICAL EVALUATION;
D O I
10.1016/j.ejmech.2018.05.004
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Alzheimer's disease (AD), the most common form of dementia, is a multifactorial neurodegenerative disease. The target enzymes inhibition including cholinesterase, beta-secretase, monoamine oxidase and inhibition of amyloid-beta aggregation as well as oxidative stress and metal chelation play an important role in the pathogenesis of AD. Chroman-4-one scaffold with benzo-gamma-pyrone network is a privileged structure in organic synthesis and drug design. A large number of research has been carried out on modified naturally occurring chromanone scaffolds and/or synthesized new analogues, to obtain effective drugs for AD management. The present review summarizes aspects related to the multi-target directed ligands (MTDLs) strategy in enzyme targets modulation performed with natural and synthesized chroman-4-one-based structures to look at their potential in the management of multifactorial Alzheimer's disease. (C) 2018 Elsevier Masson SAS. All rights reserved.
引用
收藏
页码:570 / 589
页数:20
相关论文
共 50 条
  • [21] Development of the ?hidden? multi-target-directed ligands by AChE/BuChE for the treatment of Alzheimer?s disease
    Chen, Rui
    Li, Xinjuan
    Chen, Hongsong
    Wang, Keren
    Xue, Teng
    Mi, Jing
    Ban, Yujuan
    Zhu, Gaofeng
    Zhou, Yi
    Dong, Wu
    Tang, Lei
    Sang, Zhipei
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2023, 251
  • [22] Chromone derivatives bearing pyridinium moiety as multi-target-directed ligands against Alzheimer's disease
    Abdpour, Shahin
    Jalili-Baleh, Leili
    Nadri, Hamid
    Forootanfar, Hamid
    Bukhari, Syed Nasir Abbas
    Ramazani, Ali
    Ebrahimi, Seyed Esmaeil Sadat
    Foroumadi, Alireza
    Khoobi, Mehdi
    BIOORGANIC CHEMISTRY, 2021, 110
  • [23] Multi-target-directed ligands for Alzheimer's disease: Discovery of chromone-based monoamine oxidase/cholinesterase inhibitors
    Reis, Joana
    Cagide, Fernando
    Estrada Valencia, Martin
    Teixeira, Jose
    Bagetta, Donatella
    Perez, Concepcion
    Uriarte, Eugenio
    Oliveira, Paulo J.
    Ortuso, Francesco
    Alcaro, Stefano
    Isabel Rodriguez-Franco, Maria
    Borges, Fernanda
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 158 : 781 - 800
  • [24] Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer's Disease
    Agis-Torres, Angel
    Soellhuber, Monica
    Fernandez, Maria
    Sanchez-Montero, J. M.
    CURRENT NEUROPHARMACOLOGY, 2014, 12 (01) : 2 - 36
  • [25] Identifying natural compounds as multi-target-directed ligands against Alzheimer's disease: an in silico approach
    Ambure, Pravin
    Bhat, Jyotsna
    Puzyn, Tomasz
    Roy, Kunal
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2019, 37 (05): : 1282 - 1306
  • [26] Tacripyrimidines, the first tacrine-dihydropyrimidine hybrids, as multi-target-directed ligands for Alzheimer's disease
    Chioua, Mourad
    Buzzi, Eleonora
    Moraleda, Ignacio
    Iriepa, Isabel
    Maj, Maciej
    Wnorowski, Artur
    Giovannini, Catia
    Tramarin, Anna
    Portali, Federica
    Ismaili, Lhassane
    Lopez-Alvarado, Pilar
    Laura Bolognesi, Maria
    Jozwiak, Krzysztof
    Carlos Menendez, J.
    Marco-Contelles, Jose
    Bartolini, Manuela
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 155 : 839 - 846
  • [27] Tacrine-resveratrol fused hybrids as multi-target-directed ligands against Alzheimer's disease
    Jerabek, Jakub
    Uliassi, Elisa
    Guidotti, Laura
    Korabecny, Jan
    Soukup, Ondrej
    Sepsova, Vendula
    Hrabinova, Martina
    Kuca, Kamil
    Bartolini, Manuela
    Pena-Altamira, Luis Emiliano
    Petralla, Sabrina
    Monti, Barbara
    Roberti, Marinella
    Bolognesi, Maria Laura
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2017, 127 : 250 - 262
  • [28] Discovery of novel hybrids containing clioquinol-1-benzyl-1,2,3,6-tetrahydropyridine as multi-target-directed ligands (MTDLs) against Alzheimer's disease
    Li, Xinnan
    Li, Tiantian
    Zhang, Pengfei
    Li, Xinuo
    Lu, Li
    Sun, Yuan
    Zhang, Bocheng
    Allen, Stephanie
    White, Lisa
    Phillips, James
    Zhu, Zheying
    Yao, Hequan
    Xu, Jinyi
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 244
  • [29] Multi-target-directed ligands for treating Alzheimer's disease: Butyrylcholinesterase inhibitors displaying antioxidant and neuroprotective activities
    Knez, Damijan
    Coquelle, Nicolas
    Pislar, Anja
    Zakelj, Simon
    Jukic, Marko
    Sova, Matej
    Mravljak, Janez
    Nachon, Florian
    Brazzolotto, Xavier
    Kos, Janko
    Colletier, Jacques-Philippe
    Gobec, Stanislav
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2018, 156 : 598 - 617
  • [30] Tacrine hybrids as multi-target-directed ligands in Alzheimer’s disease: influence of chemical structures on biological activities
    Małgorzata Girek
    Paweł Szymański
    Chemical Papers, 2019, 73 : 269 - 289